Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
It will focus on interface between API and formulation manufacturing, reducing carbon footprint in formulation production, creating intellectual property, training next-generation scientists, and setting new industry benchmarks
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
As with any medicine, the MHRA will keep the safety of gepotidacin under close review
Subscribe To Our Newsletter & Stay Updated
